Program for Innovative Microbiome and Translational Research

PRIME-TR aims to position MD Anderson as a pioneer in transforming cancer therapy through the modulation of the human microbiome

The focus of  the Program for Innovative Microbiome and Translational Research (PRIME-TR) is to enable and support high-impact, microbiome-based profiling and interventional trials with the goal of understanding microbe-host interactions in the context of cancer onset, progression, and response to treatment.

The mission of PRIME-TR is to build a robust framework that enables a concerted effort for translational research by leveraging existing resources at our institution and by developing programs and relationships to support novel translational applications in the microbiome space. Our ultimate goal is to improve prevention, diagnosis, and treatment strategies for cancer patients and the at-risk population. Succeeding at this vision would result in the ability to treat a wider patient population via novel and improved strategies based upon microbiome applications.